Login to Your Account



Oncology Progress Continues

Cephalon Submits Treanda NDA: Orphan Drug For CLL

By Randall Osborne


Monday, September 24, 2007
On the heels of the FDA nod for Genzyme Corp.'s Campath for first-line use in chronic B-cell lymphocytic leukemia, Cephalon Inc. submitted its new drug application for the orphan drug Treanda, which targets CLL and is being developed for non-Hodgkin's lymphoma as well. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription